8-(6-iodopyridazin-3-yl)-10-methyl-8,10-diazabicyclo[4.3.1]decane | 958882-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 8-(6-iodopyridazin-3-yl)-10-methyl-8,10-diazabicyclo[4.3.1]decane
• 英文别名: 8-(6-Iodo-pyridazin-3-yl)-10-methyl-8,10-diaza-bicyclo[4.3.1]-decane
• CAS: 958882-44-5
• 化学式: C₁₃H₁₉IN₄
• 分子量: 358.225
• InChiKey: KKGVKNKIMFVGMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-(6-iodopyridazin-3-yl)-10-methyl-8,10-diazabicyclo[4.3.1]decane 、 富马酸 在 Palladacycle copper(l) iodide 、 二异丙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 甲醇 、 乙醚 为溶剂， 反应 19.0h， 以41%的产率得到10-methyl-8-(6-phenylethynyl-pyridazin-3-yl)-8,10-diaza-bicyclo[4.3.1]decane fumaric acid salt
  参考文献：
  名称：

  WO2007/135121

  摘要：

  公开号：

文献信息

• NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE
  申请人：Peters Dan

  公开号：US20090099153A1

  公开（公告）日：2009-04-16

  This invention relates to novel 8,10-diaza-bicyclo[4.3.1]decane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的8,10-二氮杂双环[4.3.1]十碳烷衍生物，发现它们是尼古丁酸乙酰胆碱受体的胆碱能配体。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统相关的疾病或疾病有关的平滑肌收缩、内分泌疾病或疾病、神经退行性疾病或疾病、炎症、疼痛和化学物质滥用终止引起的戒断症状等多种不同的疾病或疾病具有用处。
• 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
  申请人：Neurosearch A/S

  公开号：US07910578B2

  公开（公告）日：2011-03-22

  This invention relates to novel 8,10-diaza-bicyclo[4.3.1]decane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新颖的8,10-二氮杂双环[4.3.1]癸烷衍生物，发现它们是尼古丁乙酰胆碱受体的胆碱能配体。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或疾病、内分泌疾病或疾病、神经退行性疾病或疾病、炎症、疼痛以及由于化学物质滥用终止引起的戒断症状等多种疾病或疾病具有用处。
• NOVEL 8,10-DIAZA-BICYCLOÝ4.3.1¨DECANE DERIVATIVES AND THEIR MEDICAL USE
  申请人：NeuroSearch A/S

  公开号：EP2029607A1

  公开（公告）日：2009-03-04
• US7910578B2
  申请人：——

  公开号：US7910578B2

  公开（公告）日：2011-03-22
• [EN] NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE<br/>[FR] NOUVEAUX DÉRIVÉS DE 8,10-DIAZA-BICYCLO[4.3.1]DÉCANE ET LEUR UTILISATION MÉDICALE
  申请人：NEUROSEARCH AS

  公开号：WO2007135121A1

  公开（公告）日：2007-11-29

  [EN] This invention relates to novel 8,10-diaza-bicyclo[4.3.1]decane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
  [FR] L'invention concerne de nouveaux dérivés de 8,10-diaza-bicyclo[4.3.1]décane, dont on a constaté qu'ils étaient des ligands cholinergiques pour les récepteurs nicotiniques de l'acétylcholine. Compte tenu de leur profil pharmacologique, les composés de l'invention peuvent convenir pour le traitement de maladies et de troubles aussi divers que ceux en rapport avec le système cholinergique du système nerveux central, du système nerveux périphérique, de maladies ou de troubles relatifs à la contraction des muscles lisses, de maladies ou de troubles endocriniens, de maladies ou de troubles en rapport avec la neurodégénérescence, ainsi que de maladies ou de troubles en rapport avec une inflammation, une douleur ou des symptômes de sevrage provoqués par l'arrêt de l'abus de substances chimiques.